CGTX
- Cognition Therapeutics, Inc.
()
Overview
Company Summary
Cognition Therapeutics, Inc. (CGTX) is a biopharmaceutical company that focuses on the development of innovative treatments for neurodegenerative diseases, primarily Alzheimer's disease. The company is dedicated to discovering and developing small molecule drugs that target the toxic proteins involved in the cognitive decline seen in Alzheimer's patients.
CGTX utilizes proprietary technology platforms to identify novel drug candidates that aim to improve cognitive function and slow disease progression. The company's research primarily focuses on disrupting the misfolding and aggregation of proteins like beta-amyloid and tau, which play a central role in the development of Alzheimer's disease.
Cognition Therapeutics conducts preclinical and clinical studies to evaluate the safety and efficacy of its drug candidates. These studies involve collaboration with leading academic institutions, research organizations, and pharmaceutical partners.
The ultimate goal of Cognition Therapeutics is to bring effective and safe treatments to patients suffering from Alzheimer's disease and other neurodegenerative disorders. By targeting the underlying causes of cognitive decline, the company aims to improve the quality of life for those affected by these debilitating conditions.